Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Proteomics International Laboratories Ltd. ( (AU:PIQ) ) is now available.
Proteomics International Laboratories Ltd has released its annual report for 2025, highlighting its focus on diseases such as esophageal cancer, oxidative stress, endometriosis, and diabetic kidney disease. The company’s mission is to enhance disease treatment through early detection and innovative solutions, which could significantly impact its operations and industry positioning by potentially offering new diagnostic tools and treatments for these conditions.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a medical technology company that specializes in predictive diagnostics and advanced analytical services using proteomics, which is the large-scale study of proteins’ structure and function. The company focuses on improving the quality of lives by creating innovative tools for better disease treatment.
Average Trading Volume: 368,695
Technical Sentiment Signal: Sell
Current Market Cap: A$51.56M
See more data about PIQ stock on TipRanks’ Stock Analysis page.